Literature DB >> 11761471

Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia.

D H Geschwind1, J Robidoux, M Alarcón, B L Miller, K C Wilhelmsen, J L Cummings, Z S Nasreddine.   

Abstract

Dementia is typically thought of as a disease caused by the process of aging. Few studies have addressed the premorbid neuropsychological alterations in subjects at risk for the disease--an issue of great importance for the understanding and treatment of degenerative dementias. We used knowledge of the mutation carrier status in a family with inherited dementia to address this issue more efficiently than is possible in the general population, or in cases of inherited dementia where the mutational basis is unknown. Standard neuropsychological tests were used to detect evidence of dysfunction in frontal executive systems in 10 presymptomatic subjects with known mutation carrier status in the highly penetrant condition, frontotemporal dementia and parkinsonism linked to chromosome 17. Presymptomatic carriers demonstrated cognitive dysfunction that was not present in 6 nonmutation-carrying relatives. Strikingly, frontal-executive dysfunction was apparent in some of the youngest mutation carriers many decades prior to the predicted onset of dementia. Thus, this dysfunction may reflect the native cognitive capacities of affected subjects. These results suggest a potentially important neurodevelopmental component to a dementing condition that has been predominantly considered to be a disease of aging; accordingly, this issue warrants study in other families to assess the applicability of these findings.

Entities:  

Mesh:

Year:  2001        PMID: 11761471     DOI: 10.1002/ana.10024

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  34 in total

1.  Heritability of lobar brain volumes in twins supports genetic models of cerebral laterality and handedness.

Authors:  Daniel H Geschwind; Bruce L Miller; Charles DeCarli; Dorit Carmelli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

2.  Quantitative classification of primary progressive aphasia at early and mild impairment stages.

Authors:  M-Marsel Mesulam; Christina Wieneke; Cynthia Thompson; Emily Rogalski; Sandra Weintraub
Journal:  Brain       Date:  2012-04-23       Impact factor: 13.501

3.  Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling.

Authors:  Ezra Y Rosen; Eric M Wexler; Revital Versano; Giovanni Coppola; Fuying Gao; Kellen D Winden; Michael C Oldham; Lauren Herl Martens; Ping Zhou; Robert V Farese; Daniel H Geschwind
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

4.  Neuropsychological function in nondemented carriers of presenilin-1 mutations.

Authors:  J M Ringman; C Diaz-Olavarrieta; Y Rodriguez; M Chavez; L Fairbanks; F Paz; A Varpetian; H C Maldonado; M A Macias-Islas; J Murrell; B Ghetti; C Kawas
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

5.  Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.

Authors:  J L Whitwell; C R Jack; B F Boeve; M L Senjem; M Baker; R Rademakers; R J Ivnik; D S Knopman; Z K Wszolek; R C Petersen; K A Josephs
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

6.  Neurodegenerative diseases target large-scale human brain networks.

Authors:  William W Seeley; Richard K Crawford; Juan Zhou; Bruce L Miller; Michael D Greicius
Journal:  Neuron       Date:  2009-04-16       Impact factor: 17.173

7.  Executive function, more than global cognition, predicts functional decline and mortality in elderly women.

Authors:  Julene K Johnson; Li-Yung Lui; Kristine Yaffe
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-10       Impact factor: 6.053

8.  Of brain and bone: the unusual case of Dr. A.

Authors:  J Narvid; M L Gorno-Tempini; A Slavotinek; S J Dearmond; Y H Cha; B L Miller; K Rankin
Journal:  Neurocase       Date:  2009-06       Impact factor: 0.881

9.  Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Authors:  Adam M Staffaroni; Lynn Bajorek; Kaitlin B Casaletto; Yann Cobigo; Sheng-Yang M Goh; Amy Wolf; Hilary W Heuer; Fanny M Elahi; Peter A Ljubenkov; Reilly Dever; John Kornak; Brian Appleby; Jessica Bove; Yvette Bordelon; Patrick Brannelly; Danielle Brushaber; Christina Caso; Giovanni Coppola; Christina Dheel; Bradford C Dickerson; Susan Dickinson; Sophia Dominguez; Kimiko Domoto-Reilly; Kelly Faber; Jessica Ferrall; Julie A Fields; Ann Fishman; Jamie Fong; Tatiana Foroud; Leah K Forsberg; Ralitza Gavrilova; Debra Gearhart; Behnaz Ghazanfari; Nupur Ghoshal; Jill Goldman; Jonathan Graff-Radford; Neill Graff-Radford; Ian Grant; Murray Grossman; Dana Haley; Ging-Yuek Hsiung; Edward D Huey; David J Irwin; David T Jones; Lynne Jones; Kejal Kantarci; Anna Karydas; Daniel I Kaufer; Diana R Kerwin; David S Knopman; Ruth Kraft; Walter K Kremers; Walter A Kukull; Irene Litvan; Diane Lucente; Codrin Lungu; Ian R Mackenzie; Miranda Maldonado; Masood Manoochehri; Scott M McGinnis; Emily McKinley; Mario F Mendez; Bruce L Miller; Namita Multani; Chiadi Onyike; Jaya Padmanabhan; Alex Pantelyat; Rodney Pearlman; Len Petrucelli; Madeline Potter; Rosa Rademakers; Eliana Marisa Ramos; Katherine P Rankin; Katya Rascovsky; Erik D Roberson; Emily Rogalski; Pheth Sengdy; Leslie M Shaw; Jeremy Syrjanen; M Carmela Tartaglia; Nadine Tatton; Joanne Taylor; Arthur Toga; John Q Trojanowski; Sandra Weintraub; Ping Wang; Bonnie Wong; Zbigniew Wszolek; Adam L Boxer; Brad F Boeve; Joel H Kramer; Howard J Rosen
Journal:  Alzheimers Dement       Date:  2019-05-11       Impact factor: 21.566

10.  Impaired cognition and attention in adults: pharmacological management strategies.

Authors:  Hervé Allain; Yvette Akwa; Lucette Lacomblez; Alain Lieury; Danièle Bentué-Ferrer
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.